• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Xopenex (levalbuterol HCl) Inhalation Solution Concentrate, 1.25 mg/0.5 mL

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – September 2012

 

Summary View

ADVERSE REACTIONS

Postmarketing Adverse Reactions
  • metabolic acidosis.....added